Yahoo
NasdaqCM - Nasdaq Real Time Price USD

bioAffinity Technologies, Inc. (BIAF)

2.9100 -0.1200 (-3.96%)
At close: October 30 at 4:00:01 PM EDT
2.9000 -0.0100 (-0.34%)
After hours: October 30 at 7:48:05 PM EDT
Chart Range Bar
Loading chart for BIAF
  • Previous Close 3.0300
  • Open 2.9700
  • Bid 4.7500 x 100
  • Ask 3.5800 x 100
  • Day's Range 2.8612 - 2.9900
  • 52 Week Range 2.6600 - 80.7000
  • Volume 46,401
  • Avg. Volume 3,721,076
  • Market Cap (intraday) 3.734M
  • Beta (5Y Monthly) -1.25
  • PE Ratio (TTM) --
  • EPS (TTM) -109.3500
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

bioaffinitytech.com

57

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BIAF
83.56%
S&P 500 (^GSPC)
10.73%

1-Year Return

BIAF
92.05%
S&P 500 (^GSPC)
11.11%

3-Year Return

BIAF
99.45%
S&P 500 (^GSPC)
81.91%

5-Year Return

BIAF
99.92%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY25
Revenue 1.45M
Earnings -5.05M
Profit Margin -349.30%

Q4

FY24

Q1

FY25

Q2

FY25

Q3

FY25

-4M
-2M
0
2M
-300.0%
-250.0%
-200.0%
-150.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -257.33%

  • Return on Assets (ttm)

    -125.11%

  • Return on Equity (ttm)

    -1,860.15%

  • Revenue (ttm)

    5.9M

  • Net Income Avi to Common (ttm)

    -15.19M

  • Diluted EPS (ttm)

    -109.3500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.43M

  • Total Debt/Equity (mrq)

    38.08%

  • Levered Free Cash Flow (ttm)

    -6.91M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: